- Home
- NPCT vs TNGX Comparison
NPCT vs TNGX Comparison
Compare NPCT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- TNGX
- Stock Information
- Founded
- NPCT 2020
- TNGX 2014
- Country
- NPCT United States
- TNGX United States
- Employees
- NPCT N/A
- TNGX N/A
- Industry
- NPCT Investment Managers
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NPCT Finance
- TNGX Health Care
- Exchange
- NPCT Nasdaq
- TNGX Nasdaq
- Market Cap
- NPCT 306.8M
- TNGX 351.2M
- IPO Year
- NPCT N/A
- TNGX N/A
- Fundamental
- Price
- NPCT $10.96
- TNGX $4.97
- Analyst Decision
- NPCT
- TNGX Strong Buy
- Analyst Count
- NPCT 0
- TNGX 6
- Target Price
- NPCT N/A
- TNGX $12.20
- AVG Volume (30 Days)
- NPCT 107.1K
- TNGX 3.9M
- Earning Date
- NPCT 01-01-0001
- TNGX 08-06-2025
- Dividend Yield
- NPCT 9.82%
- TNGX N/A
- EPS Growth
- NPCT N/A
- TNGX N/A
- EPS
- NPCT N/A
- TNGX N/A
- Revenue
- NPCT N/A
- TNGX $40,990,000.00
- Revenue This Year
- NPCT N/A
- TNGX N/A
- Revenue Next Year
- NPCT N/A
- TNGX N/A
- P/E Ratio
- NPCT N/A
- TNGX N/A
- Revenue Growth
- NPCT N/A
- TNGX 10.09
- 52 Week Low
- NPCT $8.58
- TNGX $1.03
- 52 Week High
- NPCT $10.63
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- NPCT 67.73
- TNGX 70.69
- Support Level
- NPCT $10.55
- TNGX $4.70
- Resistance Level
- NPCT $10.75
- TNGX $5.63
- Average True Range (ATR)
- NPCT 0.11
- TNGX 0.60
- MACD
- NPCT 0.01
- TNGX 0.03
- Stochastic Oscillator
- NPCT 95.35
- TNGX 73.71
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.